bluebird could fare better with its new cell-based gene therapy for SCD, Lyfgenia (lovotibeglogene autotemcel), which was cleared by the FDA in December and has a list price of $3.1 million.

as well as Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia – both autologous cell therapies that seek to address the underlying genetic defect in SCD. Adakveo has, however ...

In addition, a second gene therapy, Lyfgenia, was also approved in 2023. Lyfgenia uses a lentiviral vector to synthesise haemoglobin production in erythroid precursor cells. As with Casgevy, this drug ...

After hours: March 7 at 7:59:47 PM EST Loading Chart for BLUE ...

After hours: 7:59:47 p.m. EST ...